CD8A and neoplasm: The deleterious effects of systemic EZH2 inhibition on CD8+ T cell function and proliferation70, as well as the scaffolding functions of EZH2 acting independently of its methyltransferase activity62,63, may contribute to the reduced anti-tumor activity of Tazemetostat.